NanoForm Cardiovascular Therapeutics Ltd

8 articles about NanoForm Cardiovascular Therapeutics Ltd

• Nanoform grant Global STARMAP® AI License to AstraZeneca

  10/23/2023

  Nanoform Finland Plc., an innovative nanoparticle medicine-enabling company announced that it has granted AstraZeneca Plc a global online STARMAP® license.

• Nanoform 4Q and full year 2021 report: accelerating GMP growth

  2/22/2022

  The strong momentum continues: first two customer GMP projects signed, full-year gross margin exceeds 2025 target, the rapid growth in orders received and revenue recognized accelerates further, the first clear signs of economics of scale emerges, while the near-term focus shifts to triple our GMP capacity and thereafter being able to run many GMP projects in parallel.

• Nanoform signs GMP manufacturing program with TargTex following formulation success

  2/4/2022

  Nanoform, an innovative nanoparticle medicine enabling company, announced it has signed a GMP1 manufacturing program to enhance TargTex's Glioblastoma multiforme drug candidate.

• Nanoform receives ISO/IEC 27001:2013 certification for its Information Security Management System

  11/12/2021

  Nanoform, an innovative nanoparticle medicine enabling company, announced it has received ISO/IEC 27001:2013 certification for its Information Security Management System.

• Nanoform and Boehringer Ingelheim execute master services agreement

  8/3/2021

  Nanoform, an innovative nanoparticle medicine enabling company, announces that Proof of Concept studies may now be performed for Boehringer Ingelheim to assess the added value Nanoform's award-winning CESS® technology can deliver to its drug development projects.

• Nanoform Establishes US Subsidiary

  2/10/2020

  Nanoform, an innovative nanoparticle medicine enabling company, has established Nanoform USA Inc., a wholly owned subsidiary in the US.

• Nanoform Appoints Head of US Sales

  1/13/2020

  Nanoform, an innovative nanoparticle medicine enabling company, has appointed Sally Langa as Head of US Sales.

• NanoForm Cardiovascular Therapeutics Ltd, London, UK Established for the Further Development and Commercialization of Proprietary NanoActive(TM) Formulations of Two Blockbuster Drugs

  4/13/2010